Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo
© Kitamura et al; licensee BioMed Central Ltd. 2009
Received: 19 August 2009
Accepted: 2 December 2009
Published: 2 December 2009
Intravesical BCG immunotherapy is effective for preventing recurrence and progression in none muscle-invasive bladder cancer but the dosing schedule and duration of treatment remain empirical. The mechanisms by which intravesical BCG treatment mediates antitumor activity are currently poorly understood.
HeLa cell infected with Mycobacterium bovis Bacillus Calmette-Guérin(BCG) Tokyo which were different multiplicity of infection(MOI). Proliferation of HeLa cell reduced in a dose-dependent manner by live BCG. The cytoplasm of the HeLa cell showed variety lysosomal stages by internalized and interacted BCG.
Proliferated Live BCG secreted the protein and depressed the growth of tumor. The possibility for clinical introduction of BCG therapy for carcinoma reported with review of literature.
Intravesical BCG treatment has been demonstrated to be an effective therapy for superficial transitional cell carcinoma of the bladder though the mechanism of antitumor effect still remained unclear. We studied to whether the BCG depressed the growth of malignant tumor cell or not. The proliferation of HeLa cells were inhibited by dose dependent manner infected by live BCG. HeLa cell infected by live and dead Mycobacterium bovis Bacillus Calmette-Guérin(BCG) Tokyo revealed variety stage of lysosome and BCG in the cytoplasm of HeLa cell. The internalization of live BCG into the HeLa cells did not blocked by heparin and cytochalasin B. The internalized live BCG secreted the secreted-protein and depressed the growth of tumor cell. Live BCG inhibited the growth of tumor cell by internalized and then the secreted protein in cytoplasm of HeLa cells suggested the possibility of new cancer therapy made of BCG combined with the drug delivery system(DDS).
Intravesical Bacillus Calmette-Guérin(BCG) therapy has been effective in delaying or preventing recurrence and progression for transitional cell carcinoma of bladder although its outcome is still unpredictable . The report suggested that BCG interacted with tumor cells or internalized into them, and yet the role of cellular attachment has been un-established. Therefore we initiate studied using the TEM to better define for the interaction of HeLa cells with BCG and leading to the hypothesis that live BCG induced anti-tumor activity in the tumor cells. The growth inhibition of the HeLa cell was more distinct by live BCG to compare dead BCG, the cytoplasm or membrane fraction of BCG . Those indicated live BCG invaded and proliferated in the tumor cells. Since BCG infection inhibits the proliferation and differentiation of HeLa cells, question arises as to the mechanism whether inducing the bacteriological function from inside or outside. Several bacterial components have already been reported the affected proliferation by infection . The possibility remains that poor nutrition of the cells caused by intracellular proliferation of BCG as well as the BCG stimulus on the cell surface receptor may also be involved in the suppression of cellular proliferation and differentiation .
Infection and growth of live BCG in the host cell and released BCG-related cytokine were estimated as the reasons for the depression of the tumor cells. MPB70  (α antigen) known to be an immunogenic mycobacterial protein secreted in large amounts from culture filtrated of Mycobacterium bovis Bacillus Calmette-Guérin(BCG) Tokyo. This protein is thought to be crucial for binding phagocytic cell having fibronectin receptors and this function might be a direct effect of BCG immunotherapy[10, 11]. BCG is thought to bind to the bladder wall via interaction between the bacterial antigen complex and fibronectin . Similar observations with fibronectin attachment protein(FAP) demonstrated a Type I response inducing IL12 and IFNγ production in normal human peripheral blood lymphocytes. These data suggest that a Type I response is required for antitumor activity by BCG .
Antitumor effects of BCG against superficial urinary bladder cancer were known to be strong when BCG is directly infused into the bladder, but its immunological mechanisms are poorly understood . The internalization was inhibited by cytochalasin B(200 μg/ml); conditions known to inhibit phagocytosis . Heparin (1.25 U/Kg) also induced the aggregation of the local expression of fibronectin and sequentially lessen FN-mediated BCG attachment to bladder wall . But cell membrane-expressed fibronectin did not seem to be crucially involved in the internalization of BCG by transitional bladder cancer. A correlation between cellular fibronectin expression and the ability of transitional cell carcinoma to internalize BCG may be considered as a fortuitous coincidence . Our data showed the internalization of live BCG into the HeLa cells were not blocked by heparin or cytochalasin B. These phenomena suggested another possible reaction between the membrane of the HeLa cell and BCG. Further experiments will be necessary to clarify the biological relevant related between the internalization and phagocytosis or autophagy which is associated with the role of mycobacterial infection and intracellular killing of the cell . Autophagy, the process in which cellular organelles are targeted for degradation in lysosome, represents another potential tumor resistance mechanism and further adding to the complexity of cell death pathways when tumor cells are exposed to various agents [18, 19]. IFN-γ induction of autophagy has not been previously reported in immune or phagocyte cells but has been observed in HeLa cells [2, 20]. We reported that mycobacterial infection induces the Th1-type immune response lead on the immunological environment rich in IFN-α, which is a suppressive mediator of the Th2-type immune reaction . Th1-stimulating cytokines played an important role in BCG-induced macrophage cytotoxicity and that combination of BCG with selected Th1-stimulating cytokines, either supplemented or expressed by BCG, may enhance the effect of BCG in the treatment of bladder cancer patients . Early stages of BCG infection into osteoblastic-like cell (MC3T3-E1) secreted IL-6 and then depressed the proliferation of host . The findings that live BCG infected and internalized in the HeLa cells as shown here, lysosomal activity is an important connection between immune mediator and associated intracellular depression of the host cells. These data suggested that live BCG invaded and proliferated in the cell then released the BCG-related protein have direct effect to inhibit the growth of the host.
The novel method such as using target would allow further improve the bacteria to satisfy a variety of requirements for clinical use. These therapies elicit active immune response against the tumor so that they kill off primary as well as metastases . Successful cancer therapy required close contact between BCG and tumor cells, a host capable of developing and expressing delayed hypersensitivity type reactions to mycobacterial antigens, limited tumor size and an adequate number of viable BCG . It is also necessary to establish the effective drug delivery system(DDS) to be internalized into malignant cell in vivo treatment . The difference between the live and dead BCG which internalized in the cytoplasm of HeLa cell is the existence of secreted protein or not. BCG interacted with tumor cells and were internalized into them suggested future development of anti-tumor agents made from bacterial cell wall or secreted protein .
Live BCG depressed the growth of the HeLa cell by dose dependent manner.
Live BCG internalized and secreted protein in the host cell suggested the depression of tumor cell.
HeLa cell (1 × 105 cells/ml) were maintained in minimal essential medium (MEM, Gibco BRL, Tokyo Japan) supplemented with 10% fetal bovine serum and 100,000 U/1 penicillin at 37°C in humidified atmosphere with 5% CO2. The cultured medium was replaced every 3 days. Cells were rinsed 2 times with phosphates-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 8.1 mM NaH2PO4) before addition of fresh medium.
Mycobacterium bovis Bacillus Calmette-Guérin(BCG) Tokyo was cultured in Middle brock 7H9 broth (Difco Laboratories, Detroit, MI, USA) supplemented with 10% Albumin-dextrose-catalase(ADC; Difco laboratories) enrichment and 0.1% Tween 80. The cells(approximate 8 × 1010 cells/ml) were harvested with shaking at 37°C until 0.8 of an optical density(OD) at 590 nm. It was centrifuged and the pelletized cells re-suspended with MEM were divided and used for experiments. Dead BCG dosage (1 × 107 cells/ml) as MOI 100 was prepared and treated by an autoclave (121°C, 10 min).
Fraction of BCG membrane and cytoplasm 
BCG(Tokyo) was sedimented (3,000 × g, 10 min, 4°C), suspended in TMNSH buffer, and lysed by sonication in a Bioruptor UCD-200T sonicator (Toso, Tokyo, Japan). The cell lysate was centrifuged at 10,000 × g for 10 min at 4°C twice. The supernatant was then centrifuged at 30,000 × g for 30 min at 4°C. The pellet was used as the membrane fraction.
The supernatant solution was centrifuged under the same conditions, and the supernatant thus obtained was then centrifuged at 105,000 × g for two hours at 4°C. The pellet was used as the cytoplasm fraction.
The pellets obtained in each step were suspended in TMNSH buffer. Freeze drying membrane and cytoplasm fraction were prepared 0.04 μg/ml and 0.02 μg/ml respectively for the experiment as MOI 100 and keeping at the department of oral bacteriology Nagasaki University. BCG also had been cultured in the same department.
Purified MPB70 was provided by Dr. Nagai. BALB/c mice at 7-10 weeks of age were immunized intravenously with MPB 70 (10 μg diluted 200 ul of PBS) which was served as the most abundant protein in the culture filtrate from BCG(Tokyo). After 30 days, same amount of MPB 70 was injected intraperitoneally to boost the immune response. After 1 week later, sera were collected from the eye vein of immunized mice and pooled at -80°C until use. Animal had been keeping at animal center of Nagasaki Univ.
HeLa and BCG cells co-culture
Two millimeter of HeLa cells (1 × 105/ml) were inoculated in 24-well plates and cultured for 1 days. Then BCG at various doses and type were added to the wells. After 72 hours fresh MEM exchanged one ml.
Different BCG dosage even, ten and hundred times of multiplicity of infection (MOI) BCG were prepared and cultured with HeLa cell.
Growth inhibition of HeLa cell checked by its fraction of membrane (0.04 μg/ml, Dry weight) and cytoplasm (0.02 μg/ml, Dry weight) were also prepared as equivalent dosage of MOI 100 and added in the medium of HeLa cells.
Internalization of the BCG checked using each cytochalasin B (100 μg/ml, Wako pure C.I. Japan) or heparin sodium (0.001 U/ml, OSTUKA Pharm. Japan) was added into the well before co-cultured with HeLa cell respectively.
Every other day during the incubation period with the HeLa and BCG, MEM changed to the usual saline solution and treated 2% tripsin treated for 5 minutes. HeLa cells were mounted on the erythrocytometer after 0.3% trypanblue stain. The number of cells expressed as the mean for three times.
Transmission electron microscope (TEM) 
The HeLa cell washed in the normal saline solution and centrifuged. The cells were fixed in solution of 2% glutaraldehyde in 0.1 M phosphate buffer solution, pH 7.3 for 2 hours and 1% osmium tetraoxide for 2 hours. After two times washed PBS and water the cells were dehydrated with increasing concentrations of ethanol; and gradually infiltrated with Epon 812. Before inspection by TEM the trimmed bloc of epon was orientated and stained with toluidine blue for light microscopy orientation. The ultrathin section with silver to gold interference color were picked up in a nickel grid and stained with uranyl acetate and lead nitrate in the usual manner.
For Immuno-TEM HeLa cell fixed 1% paraformaldehyde at 4°C for one hour. Then dehydrated in ethanol and embedded by LR white(Okenshoji, Japan) for 2 days at -20°C. The same interference color picked up on the collodion coated mesh (Nissinn EM, Japan) specimens were reacted with 2% hydrogen peroxide for 30 minutes twice and blocked bovine serum for 30 minutes. They were reacted with hundred times diluted anti-sera (polyclonal Aanti-MPB70) for 12 hours at 8°C and protein A gold (15 nm, FUNAKOSI, Japan) for three hours at room temperature in moisture chamber and then double stained for 5 minutes each. The specimens were examined in a H800 electron microscope (Hitachi, Japan) operating at 75 kV.
- Ohara N, Naito M, Miyazaki C: HrpA, a new ribosome-associated protein which appears in heat-stressed Mycobacterium bovis Bacillus Calmette-Guérin. J Bacteriol. 1997, 179: 6495-6498.PubMed CentralPubMedGoogle Scholar
- Gutierrez G, Master SS, Singh SB: Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell. 2004, 119: 753-766. 10.1016/j.cell.2004.11.038.View ArticlePubMedGoogle Scholar
- Luo YI, Szilvasi A, Chen X: A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin Diagn Lab Immunol. 1996, 3: 761-768.PubMed CentralPubMedGoogle Scholar
- Shen Z, Wang Y, Ding GQ: Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits. World J Urol. 2007, 25: 525-529. 10.1007/s00345-007-0198-z.View ArticlePubMedGoogle Scholar
- Harboe M, Nagai N: MPB70, a unique antigen of Mycobacterium bovis BCG. Am Rev Respir Dis. 1984, 129: 444-452.PubMedGoogle Scholar
- Nagai S, Wiker HG, Harboe M: Isolation and partial characterization of Major protein antigens in the culture fluid of Mycobacterium tuberculosis. Infect Immun. 1991, 59: 372-382.PubMed CentralPubMedGoogle Scholar
- Mastumoto S, Matsuo T, Ohara N: Cloning and sequencing of a unique antigen MPT70 from Mycobacterium tuberculosis H37Rv and expression in BCG using E. coli-Mycobacteria Shuttle Vector. Scand J Immunol. 1995, 41: 281-287. 10.1111/j.1365-3083.1995.tb03565.x.View ArticleGoogle Scholar
- Decobert M, LaRue H, Harel F: Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer. How much is enough?. Cancer. 2008, 113: 710-716. 10.1002/cncr.23627.View ArticlePubMedGoogle Scholar
- Kuroda K, Brown EJ, Telle WB: Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest. 1993, 91: 69-76. 10.1172/JCI116202.PubMed CentralView ArticlePubMedGoogle Scholar
- Ohara N, Kitaura H, Hotokezaka H: Characterization of the gene encoding the MPB51, one of the major secreted protein antigens of Mycobacterium bovis BCG, and identification of the secreted protein closely related to the fibronectin binding 85 complex. Scand J Immunol. 1995, 41: 433-442. 10.1111/j.1365-3083.1995.tb03589.x.View ArticlePubMedGoogle Scholar
- Kuromatsu I, Matsuo K, Takamura S: Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an α antigen from mycobacteria. Cancer Gene Ther. 2001, 8: 483-490. 10.1038/sj.cgt.7700330.View ArticlePubMedGoogle Scholar
- Mitropoulos DN: Novel insights into the mechanism of action of intravesical immunomodulators. In vivo. 2005, 19: 611-612.PubMedGoogle Scholar
- Sinn HW, Elzey BD, Jensen RJ: The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity. Cancer Immunol Immunother. 2008, 57: 573-579. 10.1007/s00262-007-0397-x.View ArticlePubMedGoogle Scholar
- Oh BR, Jeong DW: Antitumor effects of bcg and cytokines against MBT-2 mouse bladder tumor cell. Bri J Urol. 1997, 80 (SUPPL 45):Google Scholar
- Becich MJ, Carroll S, Ratiff TL: Internalization of bacillus calmette-guerin by bladder tumor cells. J Urol. 1991, 145: 1316-1324.PubMedGoogle Scholar
- Bevers RFM, De Boer EC, Kurth H: BCG internalization in human bladder cancer cell lines, especially with regard to cell surface-expressed fibronectin. Actuel Urol. 2000, 31: 31-34.Google Scholar
- Biswas D, Qureshi OS, Lee W-Y: ATP-induced autophagy is associated with rapid killing of intracellular mycobacteria within human monocytes/macrophages. BMC Immuno. 2008, 9: 35-10.1186/1471-2172-9-35.View ArticleGoogle Scholar
- DiPaola RS, Lattime EC: Bacillus Calmette-Guerin mechanism of action: The role of immunity, apoptosis, necrosis and autophagy. J Urolo. 2007, 178: 1840-1841. 10.1016/j.juro.2007.08.063.View ArticleGoogle Scholar
- Chen N, Karantza-Wadsworth V: Role and regulation of autophagy in cancer. Biochim Biophys Acta. 2009, 1973: 1516-1523.View ArticleGoogle Scholar
- Inbal B, Bialik S, Sabanay I: DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J cell boil. 2002, 157: 455-468. 10.1083/jcb.200109094.View ArticleGoogle Scholar
- Matsumoto S, Yukitake H, Kanbara H: Mycobacterium bovis Bacillus Calmette-Guérin induces protective immunity against infection by Plasmodium yoelii at blood-stage depending on shifting immunity toward Th1 type and inducing protective IgG2a after the parasite infection. Vaccine. 2001, 19: 779-787. 10.1016/S0264-410X(00)00257-7.View ArticleGoogle Scholar
- Luo Y, Yamada H, Evanoff DP: Role of Th1-stimulating cytokines in bacillus Calmette-Guérin(BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol. 2006, 146: 181-188. 10.1111/j.1365-2249.2006.03191.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Hotokezaka H, Kitamura A, Mastumoto : Internalization of Mycobacterium bovis Bacillus Calmette-Guérin into Osteoblast-like MC3T3-EL cells and bone resorptive response of the cells against the infection. Scand J Immunol. 1998, 47: 453-458. 10.1046/j.1365-3083.1998.00318.x.View ArticlePubMedGoogle Scholar
- Wei MQ, Mengesha A, Good D: Bacterial targeted tumour therapy-dawn of a new area. Cancer Lett. 2008, 259: 16-17. 10.1016/j.canlet.2007.10.034.View ArticlePubMedGoogle Scholar
- Zbar B, Rapp HJ: Immunotherapy of guinea pig cancer with BCG. Cancer. 1974, 34: 1532-1540. 10.1002/1097-0142(197410)34:8+<1532::AID-CNCR2820340827>3.0.CO;2-H.View ArticlePubMedGoogle Scholar
- Kitamura A, Tobita T, Fuzisawa A: Evaluation on the cell-killing effects of the alpha-antigen by electroporation. Jpn J Cancer Res. 2001, 92 (Supp 555):Google Scholar
- Morales A: Evolution of intravesical immunotherapy for bladder cancer: Mycobacterial cell wall preparation as a promising agent. Expert Opin Investig Drugs. 2008, 17: 1067-1073. 10.1517/13543722.214.171.1247.View ArticlePubMedGoogle Scholar
- Kitamura A: Bleomycin-mediated electrochemotherapy in mouse NR-S1 carcinoma. Cancer Chemother Pharmacol. 2003, 51: 359-362.PubMedGoogle Scholar
- Ikeda N, Honda I, Yano I: Bacillus Calmette-Guerin Tokyo172 substrain for superficial bladder cancer: Characterization and antitumor effect. J Urolo. 2005, 173: 1507-1512. 10.1097/01.ju.0000154354.06892.ba.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.